Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Clinical Trials, Drugs (Pharmaceuticals), Food and Drug Administration, Generic Brands and Products, Inventions and Patents, Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry
←Trump Invents Another Hero Myth, This Time Making His Aides Sound Like Fools
‘Auction’ Review: The Art World’s Gilded Hustle→

More posts

  • Denmark accuses Russia of plotting to kill Ukrainian American rapper on its soil

  • Trump calls Xi and Putin a notable word, and we finally get ‘GTA VI’ after all: The news quiz

  • Anthropic’s Debut Shows the Disconnect Between Wall Street and Silicon Valley

  • Obsessive Throwbacks on G.T.A. VI and 9 More Songs We’re Talking About

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube